Experts explain the role and safety of Bayer's elinzanetant to treat vasomotor symptoms since its approval in October 2025.
James A. Simon, MD, CCD, MSCP, IF, FACOG
Advertisement
James A. Simon, MD, CCD, MSCP, IF, FACOG, Clinical Professor of Ob/Gyn at George Washington University in Washington, DC.
Articles by James A. Simon, MD, CCD, MSCP, IF, FACOG
Elinzanetant shows a strong safety profile with no liver toxicity and minimal side effects in menopausal women with vasomotor symptoms.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
CMS proposed G-codes for obstetric billing draw concern from ACOG amid coding transition
2
CDC: 15% of US women report drinking alcohol during pregnancy
3
CMS' obstetric G-codes cause confusion, perimenopause uncertainty, Zuranolone real-world data
4
National strategy calls for $20B investment to close women's health gap
5